Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “DL1 80 mg cohorts 1A and 1B (80 mg QD and 40 mg BID) DL2 160 mg cohorts 2A and 2B (160 mg QD and 80 mg BID) DL3 40 mg QD cohort C DL = dose Level QD= quaque die (once daily) BID= bis in die (twice daily)”In the company’s words, NCT03748199 on ClinicalTrials.gov
- Tested for
- Cystic Fibrosis
- Main trialPhase 1/2
- “"This is a randomised, double-blind, placebo-controlled multi-centre study to investigate safety and tolerability and to provide pharmacokinetic and pharmacodynamics information of orally inhaled multiple doses (80 mg, 160 mg or 320 mg) of the nebulised neutrophil elastase inhibitor POL6014 in patients with Cystic Fibrosis. The controlled inhalation will occur via the eFlow® nebuliser system (manufacturer: PARI Pharma GmbH, Germany)".”In the company’s words, NCT03748199 on ClinicalTrials.gov
Other drugs for Cystic Fibrosis
- ELX/TEZ/IVAVertex Pharmaceuticals · Phase 3
- IvacaftorVertex Pharmaceuticals · Phase 3
- VNZ/TEZ/D-IVAVertex Pharmaceuticals · Phase 3
- RCT2100ReCode Therapeutics · Phase 2
- SP-101Spirovant Sciences, Inc. · Phase 1/2
- 4D-7104D Molecular Therapeutics · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 30 Dec 2020 | Clinical Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of POL6014 in Patients With CF |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026